Filia Apostolakou

1 Introduction Renal amyloidosis is encountered in almost 70% of patients with immunoglobulin light chain (AL) amyloidosis. Advanced renal disease can have a detrimental effect on patients' quality of life, with a high risk of progression to end-stage renal disease requiring dialysis. The staging system that is currently used to stratify patients into three stages is based on creatinine-based estimated glomerular filtration rate (eGFR) and 24-h proteinuria [1].

CORRESPONDENCE Evangelos Terpos MD, PhD, Corresponding Author Evangelos Terpos MD, PhD eterpos@med.uoa.gr eterpos@hotmail.com orcid.org/0000-0001-5133-1422 Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece Correspondence Evangelos Terpos, MD; Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Alexandra General Hospital, 80 Vas.

Levels of the angiogenic cytokines placental growth factor (PlGF) and soluble Fms‐like tyrosine kinase‐1 (sFlt‐1) and the angiogenic balance, expressed by sFlt‐1/PlGF ratio, are perturbed in sickle‐cell disease and iron overload, but they have not been evaluated in non‐transfusion‐dependent thalassemia (NTDT).